{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:30:30Z","timestamp":1793644230551,"version":"4.5.1"},"reference-count":66,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Mouse double minute 2 homolog (MDM2) is a negative regulator of the tumor suppressor p53 and is often highly expressed in acute myeloid leukemia (AML) and other solid tumors. Inactivating mutations in TP53, the gene encoding p53, confers an unfavorable prognosis in AML and increases the risk for relapse after allogeneic hematopoietic cell transplantation. We review the concept that manipulation of MDM2 and p53 could enhance immunogenicity of AML and solid tumor cells. Additionally, we discuss the mechanisms by which MDM2 and p53 regulate the expression of major histocompatibility complex class I and II, transcription of double stranded RNA of endogenous retroviruses, responses of interferons, production of interleukin-15, and expression of tumor necrosis factor\u2013related apoptosis\u2013inducing ligand receptor 1 and 2 on malignant cells. The direct effects of MDM2 inhibition or MDM2 deletion in effector T cells are discussed in the context of cancer immunotherapy. The preclinical findings are connected to clinical studies using MDM2 inhibition to enhance antitumor immunity in patients. This review summarizes current evidence supporting the use of MDM2 inhibition to restore p53 as well as the direct effects of MDM2 inhibition on T cells as an emerging concept for combined antitumor immunotherapy against hematological malignancies and beyond.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023020731","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T17:20:15Z","timestamp":1689787215000},"page":"2701-2709","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":60,"title":["The role of the MDM2\/p53 axis in antitumor immune responses"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4387-7905","authenticated-orcid":false,"given":"Tilman","family":"Brummer","sequence":"first","affiliation":[{"name":"1Faculty of Medicine, Institute of Molecular Medicine and Cell Research, University of Freiburg, Freiburg, Germany"},{"name":"2Faculty of Medicine, Comprehensive Cancer Center Freiburg, Medical Center, University of Freiburg, Freiburg, Germany"},{"name":"3German Cancer Consortium Partner Site Freiburg and German Cancer Research Center, Heidelberg, Germany"},{"name":"4Signalling Research Centres BIOSS and Centre for Integrative Biological Signaling Studies, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-3393","authenticated-orcid":false,"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine, Comprehensive Cancer Center Freiburg, Medical Center, University of Freiburg, Freiburg, Germany"},{"name":"3German Cancer Consortium Partner Site Freiburg and German Cancer Research Center, Heidelberg, Germany"},{"name":"4Signalling Research Centres BIOSS and Centre for Integrative Biological Signaling Studies, University of Freiburg, Freiburg, Germany"},{"name":"5Department of Medicine I (Hematology, Oncology, and Stem Cell Transplantation), Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5659","key":"2024062715205097200_bib1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In\u00a0vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"2024062715205097200_bib2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12935-019-0937-4","article-title":"The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors","volume":"19","author":"Hou","year":"2019","journal-title":"Cancer Cell Int"},{"issue":"9","key":"2024062715205097200_bib3","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1182\/blood-2005-02-0553","article-title":"MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy","volume":"106","author":"Kojima","year":"2005","journal-title":"Blood"},{"key":"2024062715205097200_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.pharmtox.48.113006.094723","article-title":"Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy","volume":"49","author":"Shangary","year":"2009","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"8","key":"2024062715205097200_bib5","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1084\/jem.20080383","article-title":"Transcriptional role of p53 in interferon-mediated antiviral immunity","volume":"205","author":"Mu\u00f1oz-Fontela","year":"2008","journal-title":"J\u00a0Exp Med"},{"issue":"10","key":"2024062715205097200_bib6","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/blood.2022016082","article-title":"Targeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1\/2 upregulation","volume":"140","author":"Ho","year":"2022","journal-title":"Blood"},{"issue":"20","key":"2024062715205097200_bib7","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"2024062715205097200_bib8","first-page":"4147","article-title":"Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial","volume":"6","author":"Konopleva","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2024062715205097200_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s40425-019-0750-6","article-title":"MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment","volume":"7","author":"Fang","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"8","key":"2024062715205097200_bib10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/1541-7786.MCR-22-0898","article-title":"MDM2 inhibition enhances immune checkpoint inhibitor therapy in melanoma","volume":"21","author":"Langenbach","year":"2023","journal-title":"Mol Cancer Res"},{"issue":"6","key":"2024062715205097200_bib11","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"issue":"52","key":"2024062715205097200_bib12","doi-asserted-by":"crossref","first-page":"7729","DOI":"10.1038\/sj.onc.1209046","article-title":"SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation","volume":"24","author":"Ahuja","year":"2005","journal-title":"Oncogene"},{"issue":"21","key":"2024062715205097200_bib13","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1038\/sj.onc.1204373","article-title":"The role of tetramerization in p53 function","volume":"20","author":"Ch\u00e8ne","year":"2001","journal-title":"Oncogene"},{"issue":"6381","key":"2024062715205097200_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"Cancer. p53, guardian of the genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"key":"2024062715205097200_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","article-title":"Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice","volume":"7","author":"Hingorani","year":"2005","journal-title":"Cancer Cell"},{"key":"2024062715205097200_bib16","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: p53-p21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ"},{"key":"2024062715205097200_bib17","doi-asserted-by":"crossref","first-page":"a000935","DOI":"10.1101\/cshperspect.a000935","article-title":"Transcriptional regulation by p53","volume":"2","author":"Beckerman","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"28","key":"2024062715205097200_bib18","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1038\/onc.2016.502","article-title":"Census and evaluation of p53 target genes","volume":"36","author":"Fischer","year":"2017","journal-title":"Oncogene"},{"issue":"7","key":"2024062715205097200_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/cancers10070213","article-title":"Human oncoviruses and p53 tumor suppressor pathway deregulation at the origin of human cancers","volume":"10","author":"Tornesello","year":"2018","journal-title":"Cancers"},{"issue":"7587","key":"2024062715205097200_bib20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature16481","article-title":"Structure of the E6\/E6AP\/p53 complex required for HPV-mediated degradation of p53","volume":"529","author":"Martinez-Zapien","year":"2016","journal-title":"Nature"},{"issue":"12","key":"2024062715205097200_bib21","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2024062715205097200_bib22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Non-genomic alterations in antigen presentation and T cell costimulation are distinct drivers of leukemia immune escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"issue":"24","key":"2024062715205097200_bib23","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N\u00a0Eng J Med"},{"issue":"6","key":"2024062715205097200_bib24","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1158\/2159-8290.CD-21-0980","article-title":"Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse","volume":"12","author":"Gambacorta","year":"2022","journal-title":"Cancer Discov"},{"issue":"5168","key":"2024062715205097200_bib25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1126\/science.8016643","article-title":"Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA","volume":"265","author":"Steimle","year":"1994","journal-title":"Science"},{"issue":"4","key":"2024062715205097200_bib26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.humimm.2012.01.018","article-title":"The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferation","volume":"73","author":"Gasparini","year":"2012","journal-title":"Hum Immunol"},{"issue":"54","key":"2024062715205097200_bib27","doi-asserted-by":"crossref","first-page":"7740","DOI":"10.1038\/sj.onc.1203235","article-title":"p53 induces TAP1 and enhances the transport of MHC class I peptides","volume":"18","author":"Zhu","year":"1999","journal-title":"Oncogene"},{"issue":"12","key":"2024062715205097200_bib28","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ni1202-1121","article-title":"The final cut: how ERAP1 trims MHC ligands to size","volume":"3","author":"Falk","year":"2002","journal-title":"Nat Immunol"},{"key":"2024062715205097200_bib29","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/ncomms3359","article-title":"p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1","volume":"4","author":"Wang","year":"2013","journal-title":"Nat Commun"},{"issue":"12","key":"2024062715205097200_bib30","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1158\/2159-8290.CD-20-1741","article-title":"Pharmacological activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting anti-tumor immunity","volume":"11","author":"Zhou","year":"2021","journal-title":"Cancer Discov"},{"key":"2024062715205097200_bib31","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/nm1202-797","article-title":"T\u00a0cells require TRAIL for optimal graft-versus-tumor activity","volume":"8","author":"Schmaltz","year":"2002","journal-title":"Nat Med"},{"key":"2024062715205097200_bib32","first-page":"303","article-title":"PDL1 regulation by p53 via miR-34","volume":"108","author":"Cortez","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2024062715205097200_bib33","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1172\/JCI120803","article-title":"Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression","volume":"128","author":"Lin","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"2024062715205097200_bib34","doi-asserted-by":"crossref","first-page":"eaav4810","DOI":"10.1126\/scitranslmed.aav4810","article-title":"Clinical implications of tumor-intrinsic mechanisms regulating PD-L1","volume":"11","author":"Prestipino","year":"2019","journal-title":"Sci Transl Med"},{"issue":"11","key":"2024062715205097200_bib35","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1158\/0008-5472.CAN-20-0189","article-title":"Inhibition of MDM2 promotes antitumor responses in p53 wild-type cancer cells through their interaction with the immune and stromal microenvironment","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res"},{"issue":"4","key":"2024062715205097200_bib36","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","article-title":"Mutant p53 suppresses innate immune signaling to promote tumorigenesis","volume":"39","author":"Ghosh","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"2024062715205097200_bib37","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41467-022-28279-8","article-title":"Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy","volume":"13","author":"Xiao","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"2024062715205097200_bib38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024062715205097200_bib39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"2024062715205097200_bib40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/0008-5472.CAN-18-1397","article-title":"miR-146a controls immune response in the melanoma microenvironment","volume":"79","author":"Mastroianni","year":"2019","journal-title":"Cancer Res"},{"issue":"4","key":"2024062715205097200_bib41","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41590-021-00888-3","article-title":"The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity","volume":"22","author":"Zhou","year":"2021","journal-title":"Nat Immunol"},{"issue":"18","key":"2024062715205097200_bib42","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1038\/sj.onc.1205459","article-title":"Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53","volume":"21","author":"Mori","year":"2002","journal-title":"Oncogene"},{"issue":"18 suppl 12","key":"2024062715205097200_bib43","article-title":"Phase Ib study of a novel MDM2 inhibitor APG-115, in combination with pembrolizumab in patients with metastatic solid tumors in U.S [abstract]","author":"Tolcher","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2024062715205097200_bib44","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1056\/NEJMc1912274","article-title":"Extracorporeal photopheresis for severe immune checkpoint inhibitor-induced autoimmune colitis","volume":"382","author":"Apostolova","year":"2020","journal-title":"N\u00a0Eng J Med"},{"issue":"4","key":"2024062715205097200_bib45","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Trial of RG7112, a small-molecule MDM2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2024062715205097200_bib46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.leukres.2016.07.004","article-title":"A\u00a0phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory\/recurrent acute myelogenous leukemia (AML)","volume":"48","author":"Ravandi","year":"2016","journal-title":"Leuk Res"},{"issue":"11","key":"2024062715205097200_bib47","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.2022016362","article-title":"Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial","volume":"141","author":"Daver","year":"2023","journal-title":"Blood"},{"key":"2024062715205097200_bib48","doi-asserted-by":"crossref","first-page":"106489","DOI":"10.1016\/j.leukres.2020.106489","article-title":"Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: results from an idasanutlin phase 1\/1b study","volume":"100","author":"Yee","year":"2021","journal-title":"Leuk Res"},{"issue":"5","key":"2024062715205097200_bib49","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1007\/s10637-020-00907-4","article-title":"Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia","volume":"38","author":"Uy","year":"2020","journal-title":"Invest New Drugs"},{"issue":"5","key":"2024062715205097200_bib50","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/1078-0432.CCR-21-1295","article-title":"Results from a first-in-human phase I study of siremadlin (HDM201) in patients with advanced wild-type TP53 solid tumors and acute leukemia","volume":"28","author":"Stein","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024062715205097200_bib51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12185-022-03464-z","article-title":"Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia","volume":"117","author":"Sekiguchi","year":"2023","journal-title":"Int J Hematol"},{"issue":"13","key":"2024062715205097200_bib52","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1182\/bloodadvances.2019030916","article-title":"Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed\/refractory acute myeloid leukemia","volume":"3","author":"Erba","year":"2019","journal-title":"Blood Adv"},{"issue":"29","key":"2024062715205097200_bib53","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","article-title":"Targeting p53 in\u00a0vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer","volume":"30","author":"Lehmann","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024062715205097200_bib54","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1158\/0008-5472.CAN-12-2807","article-title":"MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models","volume":"73","author":"Tovar","year":"2013","journal-title":"Cancer Res"},{"issue":"14","key":"2024062715205097200_bib55","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm400487c","article-title":"Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development","volume":"56","author":"Ding","year":"2013","journal-title":"J\u00a0Med Chem"},{"issue":"19","key":"2024062715205097200_bib56","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1016\/j.bmcl.2016.08.010","article-title":"Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument","volume":"26","author":"Furet","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"issue":"16","key":"2024062715205097200_bib57","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1021\/acs.jmedchem.5b00810","article-title":"Discovery of a dihydroisoquinolinone derivative (NVP-CGM097): a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors","volume":"58","author":"Holzer","year":"2015","journal-title":"J\u00a0Med Chem"},{"issue":"7","key":"2024062715205097200_bib58","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1021\/acs.jmedchem.6b01665","article-title":"Discovery of 4-((3'R,4'S,5'R)-6\u2033-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2\u2033-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3\u2033-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic acid (AA-115\/APG-115): a potent and orally active murine double minute 2 (MDM2) inhibitor in clinical development","volume":"60","author":"Aguilar","year":"2017","journal-title":"J\u00a0Med Chem"},{"issue":"4","key":"2024062715205097200_bib59","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1021\/jm401753e","article-title":"Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development","volume":"57","author":"Sun","year":"2014","journal-title":"J\u00a0Med Chem"},{"issue":"10","key":"2024062715205097200_bib60","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1158\/0008-5472.CAN-17-0949","article-title":"Predictive gene signatures determine tumor sensitivity to MDM2 inhibition","volume":"78","author":"Ishizawa","year":"2018","journal-title":"Cancer Res"},{"issue":"21","key":"2024062715205097200_bib61","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1038\/sj.onc.1208419","article-title":"PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis","volume":"24","author":"Bykov","year":"2005","journal-title":"Oncogene"},{"issue":"14","key":"2024062715205097200_bib62","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024062715205097200_bib63","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10549-019-05435-1","article-title":"COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells","volume":"179","author":"Synnott","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"18","key":"2024062715205097200_bib64","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-19-0096","article-title":"COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNCC through p53-dependent and -independent mechanisms","volume":"25","author":"Lindemann","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2024062715205097200_bib65","first-page":"244","article-title":"PROTAC Degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective","volume":"1","author":"Han","year":"2022","journal-title":"Acta Mater Med"},{"key":"2024062715205097200_bib66","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1021\/acs.jmedchem.8b00909","article-title":"Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression","volume":"62","author":"Li","year":"2019","journal-title":"J\u00a0Med Chem"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/26\/2701\/2232823\/blood_bld-2023-020731-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/26\/2701\/2232823\/blood_bld-2023-020731-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T12:11:31Z","timestamp":1719490291000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/26\/2701\/496946\/The-role-of-the-MDM2-p53-axis-in-antitumor-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":66,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2024,6,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020731","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]}}}